Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 D32

AIDS

Volumn 29, Issue 8, 2015, Pages 867-876

  Henrich, Timothy J ^a,b   Hanhauser, Emily ^a   Hu, Zixin ^a   Stellbrink, Hans Jurgen ^c   Noah, Christian ^d   Martin, Jeffrey N ^e   Deeks, Steven G ^e   Kuritzkes, Daniel R ^a,b   Pereyra, Florencia ^a,b,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Infektionsmedizinisches Centrum Hamburg   (Germany)

^d Labor Lademannbogen   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

CCR5; CCR5 D32 mutation; HIV controller; HIV tropism; HIV 1; Viral coreceptor

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; HLA ANTIGEN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ALLELE; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; ESCAPE MUTATION; GENOME ANALYSIS; GENOTYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PHYLOGENETIC TREE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEXUALITY; VIRAL TROPISM; VIRUS ENTRY; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSMISSION; BLOOD; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MOLECULAR EVOLUTION; MUTATION; VIREMIA; VIROLOGY;

CD4 LYMPHOCYTE COUNT; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PHENOTYPE; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84979860400     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000629     Document Type: Article

References (50)

1. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563 571.
2. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, Berlusconi A, et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997; 11:F67 71.
3. Gray L, Churchill MJ, Keane N, Sterjovski J, Ellett AM, Purcell DF, et al. Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele. J Virol 2006; 80:3684 3691.
4. O Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael NL, et al. HIV-1 infection in a man homozygous for CCR5 delta Lancet 1997; 349:1219.
5. Riddick NE, Hermann EA, Loftin LM, Elliott ST, Wey WC, Cervasi B, et al. A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. PLoS Pathog 2010; 6:e1001064.
6. Rucker J, Edinger AL, Sharron M, Samson M, Lee B, Berson JF, et al. Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J Virol 1997; 71:8999 9007.
7. Sheppard HW, Celum C, Michael NL, O Brien S, Dean M, Carrington M, et al. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: Acquisition of syncytiuminducing virus at seroconversion. J Acquir Immune Defic Syndr 2002; 29:307 313.
8. Shimizu N, Tanaka A, Oue A, Mori T, Ohtsuki T, Apichartpiyakul C, et al. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS 2009; 23:761 769.
9. Steinfelder S, Floess S, Engelbert D, Haeringer B, Baron U, Rivino L, et al. Epigenetic modification of the human CCR6 gene is associated with stable CCR6 expression in T cells. Blood 2011; 117:2839 2846.
10. Gorry PR, Zhang C, Wu S, Kunstman K, Trachtenberg E, Phair J, et al. Persistence of dual-Tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet 2002; 359:1832 1834.
11. Oh DY, Jessen H, Kucherer C, Neumann K, Oh N, Poggensee G, et al. CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PLoS One 2008; 3:e2747.
12. Iversen AK, Christiansen CB, Attermann J, Eugen-Olsen J, Schulman S, Berntorp E, et al. Limited protective effect of the CCR5Delta32/CCR5Delta32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus. J Infect Dis 2003; 187:215 225.
13. Heiken H, Becker S, Bastisch I, Schmidt RE. HIV-1 infection in a heterosexual man homozygous for CCR-5 deltaAIDS 1999; 13:529 530.
14. Kuipers H, Workman C, Dyer W, Geczy A, Sullivan J, Oelrichs R. An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3 A allele. AIDS 1999; 13:433 434.
15. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997; 3:252 253.
16. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C. HIV-1 infection in an individual homozygous for CCR5 delta
17. Seroco Study Group. Lancet 1997; 349:1219 1220.
18. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621 628.
19. Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M, Lail AE, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643 649.
20. Delobel P, Sandres-Saune K, Cazabat M, Pasquier C, Marchou B, Massip P, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38:382 392.
21. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4R cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681 688.
22. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968 974.
23. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-Tropic virus population. J Virol 1992; 66:1354 1360.
24. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277:959 965.
25. Moore JP, Kitchen SG, Pugach P, Zack JA. The CCR5 and CXCR4 coreceptors: central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004; 20:111 126.
26. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-Term control of HIV by CCR5Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692 698.
27. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidencefor the cure ofHIVinfection byCCR5{Delta}32/ {Delta}32 stem cell transplantation. Blood 2011; 117: 2791 2799.
28. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014; 370:901 910.
29. Mosier DE. How HIV changes its tropism: evolution and adaptation? Curr Opin HIV AIDS 2009; 4:125 130.
30. Kordelas L, Verheyen J, Beelen DW, Horn PA, Heinold A, Kaiser R, et al. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med 2014; 371:880 882.
31. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, Inoue R, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73:2343 2349.
32. Cashin K, Jakobsen MR, Sterjovski J, Roche M, Ellett A, Flynn JK, et al. Linkages between HIV-1 specificity for CCR5 or CXCR4 and in vitro usage of alternative coreceptors during progressive HIV-1 subtype C infection. Retrovirology 2013; 10:98.
33. Islam S, Shimizu N, Hoque SA, Jinno-Oue A, Tanaka A, Hoshino H. CCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses. PLoS One 2013; 8:e73116.
34. Nedellec R, Coetzer M, Shimizu N, Hoshino H, Polonis VR, Morris L, et al. Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J Virol 2009; 83:8353 8363.
35. Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, et al. Quantification of entry phenotypes of macrophagetropic HIV-1 across a wide range of CD4 densities. J Virol 2014; 88:1858 1869.
36. Jiang C, Parrish NF, Wilen CB, Li H, Chen Y, Pavlicek JW, et al. Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol 2011; 85:10669 10681.
37. Gorry PR, Dunfee RL, Mefford ME, Kunstman K, Morgan T, Moore JP, et al. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology 2007; 362:163 178.
38. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551 1557.
39. Muxel SM, Borelli SD, Amarante MK, Voltarelli JC, Aoki MN, de Oliveira CE, et al. Association study of CCR5 delta 32 polymorphism among the HLA-DRB1 Caucasian population in Northern Parana, Brazil. J Clin Lab Anal 2008; 22:229 233.
40. Henrich TJ, Tsibris AM, Lewine NR, Konstantinidis I, Leopold KE, Sagar M, et al. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic Syndr 2010; 55:420 427.
41. Lin NH, Negusse DM, Beroukhim R, Giguel F, Lockman S, Essex M, et al. The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods 2010; 169:39 46.
42. Sanders-Buell E, Salminen MO, McCutchan FE. Sequencing primers for HIV-In: The human retroviruses and AIDS 1995 compendium: The HIV sequence database and analysis project; 19pp. III.15 III.21.
43. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25:1407 1410.
44. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552 7557.
45. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, et al. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis 2011; 203:976 983.
46. Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, et al. Identification of dominant optimal HLA-B60-and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. J Virol 2000; 74:8541 8549.
47. Teixeira SL, de Sa NB, Campos DP, Coelho AB, Guimaraes ML, Leite TC, et al. Association of the HLA-BM52 allele with nonprogression to AIDS in Brazilian HIV-1-infected individuals. Genes Immun 2014; 15:256 262.
48. Almeida CA, Bronke C, Roberts SG, McKinnon E, Keane NM, Chopra A, et al. Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-Adapted variant epitopes. J Immunol 2011; 187:2502 2513.
49. Nedellec R, Coetzer M, Lederman MM, Offord RE, Hartley O, Mosier DE. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use. PLoS One 2011; 6:e22020.
50. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909 4920